Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy
暂无分享,去创建一个
[1] James J. Collins,et al. Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.
[2] B. Demple,et al. Redox Signal Transduction: Mutations Shifting [2Fe-2S] Centers of the SoxR Sensor-Regulator to the Oxidized Form , 1997, Cell.
[3] C. Merril,et al. The prospect for bacteriophage therapy in Western medicine , 2003, Nature Reviews Drug Discovery.
[4] Nicholas J. Guido,et al. A bottom-up approach to gene regulation , 2006, Nature.
[5] D. Endy,et al. Refactoring bacteriophage T7 , 2005, Molecular systems biology.
[6] R. Wise. The relentless rise of resistance? , 2004, The Journal of antimicrobial chemotherapy.
[7] J. Smith,et al. 4-quinolones and the SOS response. , 1989, Journal of medical microbiology.
[8] J. W. Little,et al. Identification of the lexA gene product of Escherichia coli K-12. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[9] S. Leibler,et al. Bacterial Persistence as a Phenotypic Switch , 2004, Science.
[10] Stanley N Cohen,et al. SOS Response Induction by ß-Lactams and Bacterial Defense Against Antibiotic Lethality , 2004, Science.
[11] J. Heitman,et al. Phage Trojan horses: a conditional expression system for lethal genes. , 1989, Gene.
[12] Ron Weiss,et al. Engineering life: building a fab for biology. , 2006, Scientific American.
[13] James J. Collins,et al. A Tunable Genetic Switch Based on RNAi and Repressor Proteins for Regulating Gene Expression in Mammalian Cells , 2007, Cell.
[14] Thomas D. Schneider,et al. OxyR and SoxRS Regulation offur , 1999, Journal of bacteriology.
[15] J. Collins,et al. Mistranslation of Membrane Proteins and Two-Component System Activation Trigger Antibiotic-Mediated Cell Death , 2008, Cell.
[16] Ehud Shapiro,et al. Tapping the computing power of biological molecules gives rise to tiny machines that can speak directly to living cells. , 2006, Scientific American.
[17] Christopher A. Voigt,et al. Environmentally controlled invasion of cancer cells by engineered bacteria. , 2006, Journal of molecular biology.
[18] Gregory Stephanopoulos,et al. A linguistic model for the rational design of antimicrobial peptides , 2006, Nature.
[19] H. Bujard,et al. Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. , 1997, Nucleic acids research.
[20] Boris Hayete,et al. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli , 2007 .
[21] G. Walker. Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli. , 1984, Microbiological reviews.
[22] U. Bläsi,et al. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. , 2006, Microbial drug resistance.
[23] Paul Stoodley,et al. Bacterial biofilms: from the Natural environment to infectious diseases , 2004, Nature Reviews Microbiology.
[24] U. Bläsi,et al. Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage , 2004, Antimicrobial Agents and Chemotherapy.
[25] Ehud Shapiro,et al. Bringing DNA computers to life , 2006 .
[26] G. Poźniak,et al. Preparation of endotoxin-free bacteriophages. , 2004, Cellular & molecular biology letters.
[27] C. Merril,et al. Long-circulating bacteriophage as antibacterial agents. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[28] S Bonhoeffer,et al. Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[29] A. Fauci,et al. The challenge of emerging and re-emerging infectious diseases , 2004, Nature.
[30] U. Bläsi,et al. Genetically modified filamentous phage as bactericidal agents: a pilot study , 2003, Letters in applied microbiology.
[31] Floyd E Romesberg,et al. Open access, freely available online PLoS BIOLOGY Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance , 2022 .
[32] S. Mitsuhashi,et al. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.
[33] J. Costerton,et al. Antibiotic resistance of bacteria in biofilms , 2001, The Lancet.
[34] B. Weiss,et al. SoxR, a [2Fe-2S] transcription factor, is active only in its oxidized form. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] H. Brüssow,et al. Phage therapy: the Escherichia coli experience. , 2005, Microbiology.
[36] Fredrik H. Karlsson,et al. Genome-wide comparison of phage M13-infected vs. uninfected Escherichia coli. , 2005, Canadian journal of microbiology.
[37] J. Collins,et al. A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics , 2007, Cell.
[38] C. Walsh. Opinion — anti-infectives: Where will new antibiotics come from? , 2003, Nature Reviews Microbiology.
[39] R. Schleif. Fine-structure deletion map of the Escherichia coli L-arabinose operon. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Elson,et al. Strong Purifying Selection in Transmission of Mammalian Mitochondrial DNA , 2008, PLoS biology.
[41] Jeff Hasty,et al. Engineered gene circuits , 2002, Nature.
[42] R. Weiss,et al. Advances in synthetic biology: on the path from prototypes to applications. , 2005, Current opinion in biotechnology.
[43] J. Dolan,et al. Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections , 2003, Antimicrobial Agents and Chemotherapy.
[44] K. Lewis. Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.
[45] B. Demple,et al. The redox‐regulated SoxR protein acts from a single DNA site as a repressor and an allosteric activator , 1998, The EMBO journal.
[46] E. Andrianantoandro,et al. Synthetic biology: new engineering rules for an emerging discipline , 2006, Molecular systems biology.
[47] Timothy S. Ham,et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.
[48] F. Baquero,et al. Mutation Frequencies and Antibiotic Resistance , 2000, Antimicrobial Agents and Chemotherapy.
[49] J. J. Farmer,et al. Phage typing of Salmonella enteritidis in the United States , 1991, Journal of clinical microbiology.
[50] T. Romeo,et al. Biofilm Formation and Dispersal under the Influence of the Global Regulator CsrA of Escherichia coli , 2002, Journal of bacteriology.
[51] Barry G. Hall,et al. Predicting the evolution of antibiotic resistance genes , 2004, Nature Reviews Microbiology.
[52] R. Kishony,et al. Antibiotic interactions that select against resistance , 2007, Nature.
[53] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[54] C. Yanisch-Perron,et al. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.